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were used. Of these, 27 studies used telephone and text reminders. Four used 
educational materials and books while another four used blister packing. Three 
studies used interactive voice response system, two studies used letters and 
faxes, and another two studies used pill boxes. Improvement in medication 
adherence was found in all studies. The largest change in medication adherence 
was observed through the use of telephone and text reminders. CONCLUSIONS: 
Medication adherence is a problem that pharmacists are addressing through 
health care reform legislation. It’s important for pharmacists/researchers to 
educate about effective adherence tools in order to improve quality of care to 
patients and society.  
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OBJECTIVES: To explore evidence of the degree of correlation between patient 
reported outcomes (PROs) and clinician reported outcomes (ClinROs), and how 
this varies by therapeutic area, measure and language. METHODS: A review of 
the literature and analysis of existing patient registry data was conducted to 
qualitatively assess degree of correlation between PROs and ClinROs – at points 
in time, change over time, and how the relationship between these assessments 
varies by disease area and measure. A review of translation and linguistic 
validation projects involving PRO and ClinROs was also conducted to examine 
language-related differences and correlations between the scales. Specific 
examples of PRO-ClinRO pairs are given for multiple sclerosis, rheumatoid 
arthritis, and atopic eczema, among others. RESULTS: For multiple sclerosis and 
rheumatoid arthritis, moderate correlation (0.5-0.7) was found between patient 
assessments of disease severity and physician assessment, with patient 
assessments influenced by concomitant feelings (e.g., depression, anxiety). The 
correlation between patient and clinician assessment of change/responsiveness 
depends on whether an improvement or deterioration is experienced, where 
deterioration has a perceived stronger impact, patient-wise, than an 
improvement. Differences in language complexity and terminology between 
PROs and ClinROs were essential for the appropriate comprehension by the 
target population. Clinically appropriate and current terminology used for 
ClinROs was key to clinicians accepting the scale as relevant. Simple, clear 
phrasing and wording with language with lower education level was important 
for PROs. CONCLUSIONS: For reviewing PROs and ClinROs, specific differences in 
language and terminology must be taken into account, both in the development 
of instruments and linguistic validation into various target languages. In some 
disease areas, a significant and strong correlation of patient’s assessment with 
objective clinical measures may support its use as a valid proxy measure of 
clinical status, thus opening up multiple research design opportunities where 
the perspective of the patient is paramount.  
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OBJECTIVES: Crohn’s disease (CD) is an inflammatory bowel disease affecting 
approximately 1.4 million people in the United States. The aims of this study 
were to document current unmet needs in CD in terms of patient-reported and 
economic burden; and how such concepts may be assessed to capture the overall 
benefit of new CD therapies for patients, health care systems and society. 
METHODS: Articles were identified in MEDLINE, EMBASE, EconLit, HEED, CRD 
databases and PSYCINFO using pre-defined search terms/limits. 561 abstracts 
were identified; and 31 full articles were reviewed. Direct and indirect costs of 
CD were extracted as were patient-relevant concepts (symptoms and impacts) to 
form a patient-relevant conceptual model. Patient-reported measures were 
identified in PROQOLID and were assessed in context of FDA guidance. RESULTS: 
CD symptoms manifest primarily as gastrointestinal disturbances including 
abdominal pain/cramping and diarrhoea. Fever, fatigue and weight loss are also 
prominent symptoms. These symptoms impact patients’ physical functioning, 
daily activities, emotional well-being, and ability to work. Seven patient-reported 
measures were reviewed in-depth; measures of HRQoL (IBDQ, SF-36, IBDQOL), 
occupational functioning (CPWDQ, WPAI:CD) and disease activity/symptoms 
(CDAI, CDAI-short, GSRS). Instruments to assess HRQoL and occupational 
functioning used concurrently with the CDAI may demonstrate the wider 
influence of treatment on other symptoms and patients’ lives. CD is associated 
with substantial direct costs, estimated at $18-$19,000 per-patient per-year in the 
US, and indirect costs, estimated at $7,260 per-patient per-year. Costs are 
especially high in sub-groups (e.g. presence of fistulas). CONCLUSIONS: The 
disease course of CD is characterised by remissions and relapses, thus lifetime 
humanistic and economic burden is substantial. This review highlights the need 
for disease-specific patient-reported measures that provide comprehensive 
assessment of relevant domains of disease activity/symptoms, HRQoL and 
occupational functioning. Further research into drivers of direct and indirect 
costs of CD is necessary to meet cost-effectiveness requirements.  
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OBJECTIVES: The FDA approved 39 new molecular entities (NMEs) in 2012, and 
many efficacy claims were supported by patient-reported measures or 
statements. In addition, many previously-approved products were approved for 
a new indication supported by PRO endpoints in recent years. The purpose of our 
research was to conduct an in-depth analysis of recently approved claims 
supported by PROs in order to identify notable trends, and to describe best 
methods for assessing the success rate of PRO inclusion. METHODS: Published 
FDA product labels, literature and Internet searches were utilized. All labels of 
NMEs and new indications approved by the FDA from 2010 to 2012 were 
reviewed. A measure or statement of efficacy was considered to be a PRO if it 
assessed symptoms, reduced side effects, or impacts on functioning from the 
patient’s perspective. RESULTS: There were 21, 30, and 39 NMEs approved in 
2010, 2011, and 2012. In these years, 12, 19, and 13 NME labels contained PRO-
related claims or statements (67%, 63%, 33%), and pain-related PROs were the 
most common (n’s=4, 11, 8). Cumulative distribution function (CDF) graphs were 
present in 13 NME labels during these years. Importantly, from 2010 to 2012 
many products added indications with efficacy claims supported by a PRO, but 
such a submission was not considered an NME (e.g., pregabalin). From 2006 to 
2009, PRO-related claims were included in 66% of approved NMEs. This rate 
decreased to 49% during 2010 – 2012; however, more PRO claims (44 versus 50; 
2010-2012) are revealed when reviewing more than NMEs. CONCLUSIONS: 
Development, testing, and validation of PRO measures as clinical trial endpoints 
remain important for facilitating the approval of drugs and communicating value 
to the consumer. Reviewing NDA and BLA labels is a more accurate assessment 




PREDICTING MEDICATION ADHERENCE USING RETAIL PHARMACY DATA  
Dockery JD, Mueller RL 
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OBJECTIVES: Apply data mining techniques to pharmacy data to identify 
patients likely to be non-adherent to their medication in the next six months. 
METHODS: Catalina Health™ receives a nationally representative sample of 
pharmacy data containing 40% of all U.S. retail prescription volume and 130 
million unique patient ID’s. The data is HIPAA compliant, longitudinal, and not 
projected. Select 7 prescription medications representing multiple therapeutic 
classes. For each medication, randomly select a 100K patient cohort filling a 
prescription between June and August 2010. In order to eliminate patients who 
switch pharmacies or migrate to mail order, exclude patients who have no 
history of filling any drug during the prior 18 months, or who have no fill history 
for any drug during the six month analysis period. Fit logistic regression models 
to predict which patients will be non-adherent to their medication in the next 
six months. Consider patients non-adherent when Proportion of Days Covered 
(PDC)<80%. Model covariates include prior adherence to the medication (if 
applicable), adherence for co-morbid conditions, days supply of the medication, 
ethnicity and income variables, patient age and gender, paid with cash, number 
of refills remaining, medication dose, and number of co-morbidities. Model 
accuracy is assessed using a 20% hold-out of the data. RESULTS: The models 
identified 40.3% of the patients as likely to be non-adherent to their medication 
in the next six months. This varied by medication (23.2% - 64.6%) and patient 
type (28.8% Experienced, 38.9% Moderate Experienced, and 77.5% New). The 
overall model accuracy rate is 70.4%. 72.3% of the patients predicted to be non-
adherent were actually non-adherent (precision), while 69.1% of the patients 
predicted to be adherent were actually adherent. CONCLUSIONS: Data mining 
techniques applied to pharmacy data can predict patients who are likely to be 
non-adherent to their medication in the next six months with 72.3% precision.  
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OBJECTIVES: Guidelines had present many management recommendations to 
physicians on angina prevention and treatment. However patients still knew less 
about angina management in China. They need Heart education. Thus, we want 
to develop an angina patient self-management questionnaire (ASMQ). 
METHODS: We hypothesized the questionnaire should carry messages of risk 
factors, prevention and treatment of angina. Items were determined from 
guidelines, and interview of patients and cardiovascular doctors. A five point 
Likert scale was chosed as the response format. Higher score means better 
management. The questionnaire was tested along with a cross-sectional angina 
study. Reliability was evaluated via internal consistency, and test-retest 
reliability. Construct validity was tested through Exploratory Factor Analysis 
(EFA), and discriminant validity was assessed by detecting differences between 
in-patients and out-patients. We assumed in-patients learn more about angina 
than out-patients. RESULTS: The ASMQ contained 12 items organized in two 
domains: risk-factor and self-management. The ASMQ was tested on 430 
patients (age 63±12 year; 171 male, 40%); Of those, 150 (35%) were outpatients, 
and 86 (20%) retested 24 hours later. Test-rest correlation coefficient of the ASMQ 
was 0.740, and 0.719, 0.780 for risk-factor and self-management domains 
respectively. Cronbach’s alpha coefficient was 0.616 of the overall questionnaire, 
and 0.692 of the self-management domain. But the risk-factor domain was 0.432, 
showed an unsatisfied internal consistency. Three factors were extracted 
through EFA, and were stratified into 2 domains as expected. The score of in-
patients (43±7) was higher than out-patients (41±6), which showed a better 
management among in-patients (p=0.017). CONCLUSIONS: The ASMQ showed an 
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acceptable reliability and good validity, which could be used to assess angina 
self-management, and also recommended to be used as an outcome along with 
quality of life to assess clinical efficacy. The risk-factor domain would be 
modified in the further study.  
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OBJECTIVES: Fatigue is the main symptom of anemia. A blood transfusion is 
often necessary in patients with severe anemia, and fatigue will be released after 
the transfusion. However, patients with chronic anemia are often well tolerated, 
and do not feel the severe fatigue that is expected. So, how much is fatigue 
associated with anemia, and what’s the main impact influencing anemic 
fatigue? METHODS: Patients diagnosed with CAA or MDS-RA were recruited in 
an undergoing prospective observational study. Fatigue was assessed by the 
FACIT-Fatigue scale, and a higher score means better quality of life. All the 
patients filled in the Fatigue scale and ran blood tests on the day enrolled, and 
they were encouraged to be assessed by both Fatigue scale and blood test again a 
week later. The patients were divided into groups based on transfusion-
dependent, transfusion treatment, anemia level (severe<65g/L), fatigue level 
(severe<30). Chi-square or T-tests were performed between different groups. 
Pearson correlations were tested to investigate association between fatigue and 
all the possible factors. RESULTS: Thirty-eight patients (54±18 years, 12 male) 
enrolled, of those, 20 were transfusion-dependent, 14 had severe anemia, and 26 
felt severe fatigue. The anemia history was 54±78 months (median 15). 
Transfusion-dependent patients showed no difference in fatigue. Severe anemia 
patients (22±11) reported more fatigue than non-severe (27±11), but no difference 
(p=0.199). Twenty patients agreed to the reassessment; of those, 12 got 
transfusion treatment. After transfusion, the mean Hb level increased (11±8 g/L), 
and fatigue improved (8±10); as for the non-transfusion group, Hb changed (-4±13 
g/L), and fatigue changed (0±16). However, there was no difference between the 
two groups (p>0.05). Anemia history was related with fatigue (r=-0.351, p=0.031) 
and transfusion frequency (r=-0.617, p=0.001). CONCLUSIONS: Fatigue is not 
closely associated with degree of Hb and is well tolerated in chronic anemia 
patient. RBC transfusion can relieve fatigue, but a large sample is needed to 
confirm it.  
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OBJECTIVES: To compare the preference values for EQ-5D-5L health states 
between mainland Chinese and Singaporeans. METHODS: Data was from a 
multi-country health-state valuation study in which the preference values for 10 
selected EQ-5D-5L health states were elicited from a convenience sample of 
mainland Chinese in Beijing (China) as well as a convenience sample of 
Singaporeans. Each participant self-completed 5 time trade-off (TTO) tasks, each 
for a different EQ-5D-5L state, using a personal computer. The difference in TTO 
values between mainland Chinese and Singaporeans and three subgroups of 
Singaporeans (i.e. English-speaking Chinese [EC], Chinese-speaking Chinese [CC], 
and non-Chinese [NC]) was analyzed using random-effects linear regression and 
logistic regression models. RESULTS: A total of 210 mainland Chinese and 207 
Singaporeans provided data for this study. All 10 EQ-5D-5L health states 
considered, Singaporeans’ preference value was 0.146 points lower than that of 
mainland Chinese and the difference was consistent for all three subgroups of 
Singaporeans (EC: -0.156; CC: -0.195; NC: -0.073; p>0.05 for all comparisons), 
suggesting those health states were less valuable to Singaporeans than to 
mainland Chinese. Compare to mainland Chinese, Singaporeans were more 
likely to consider a health state as worse than being dead and consequently have 
a negative value to the state; the odds ratio (95% confidence interval) was 
1.31(0.54-3.53) for Singaporeans as a whole, 1.41(0.60-3.33) for EC, 1.35(0.49-3.70) 
for CC, and 1.11(0.50-3.13) for NC. For health states rated as worse than being 
dead, Singaporeans had substantial lower preference values than mainland 
Chinese, with the magnitude of difference being 0.399 for all, 0.383 for EC, 0.377 
for CC, and 0.456 for NC (P<0.05 for all comparisons). CONCLUSIONS: It appears 
that health-state preferences differ between mainland Chinese and 
Singaporeans including Singaporean Chinese. Our study supports the practice of 
developing country-specific value sets for EQ-5D-5L health states.  
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OBJECTIVES: To evaluate clinicians’ ability to understand and respond to the 
IGA-LCL, a single item severity rating scale of LCLs at neutral facial position. 
METHODS: Individual face-to-face cognitive interviews were conducted with 
seven dermatologists and one plastic surgeon from the US with experience in 
aesthetic medicine including treating LCLs. Participants attended one of two 
research sessions. At each session, the participant group received training on the 
IGA-LCL, consistent with the training provided for clinicians in phase 3 trials 
using the IGA-LCL. Two researchers then conducted individual semi-structured 
interviews with participants, following a process that required them to “think 
aloud” while reading response options and formulating a response. Interviews 
were audio-recorded and transcribed. Analyses summarized participant 
feedback on the instrument. RESULTS: Overall, findings indicate that the IGA-
LCL scale is clear and easy to use. Clinicians understood the content and were 
able to use the response options as intended. No revisions to the IGA-LCL scale 
were recommended based on results from this study, though training topics 
were identified for further emphasis and clarification. A few participants 
suggested alternate text for some response descriptions though these same 
participants understood and could use the descriptions as currently stated. One 
participant noted that she might arbitrarily define the descriptions differently 
based on her clinical experience and noted the subjectivity in making a clinical 
judgment of LCL severity, but understood and could use the IGA-LCL 
appropriately based on the training. Two participants indicated that they usually 
think about the “worst” length of wrinkle, but they could rate “average” length as 
instructed in the training. Most participants stressed the importance of training 
for proper use of the scale. CONCLUSIONS: Results support the content validity 
of the IGA-LCL. This research represents an important step toward establishing 
the content validity of the IGA-LCL relative to the FDA PRO Guidance.  
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OBJECTIVES: To describe the qualitative development of corresponding self-
reported and observer reported scales for assessing spasticity-related pain (SRP) 
experienced by children with Cerebral Palsy (CP). METHODS: The Questionnaire 
on Pain Caused by Spasticity (QPS) is a newly developed clinical outcome 
measure designed to assess SRP using corresponding versions that can be self-
administered by children (5-10 years), adolescents (11-17 years), and by parent 
caregivers (as observers of signs of pain in their children). Cognitive interviews 
were conducted to confirm appropriate understanding and the ability of children 
of various ages and CP severity to provide meaningful responses. RESULTS: Two 
children, eight adolescents, and 11 parent/caregivers participated in the 
interview sessions. Parent/caregivers were able to work with their children to 
collectively identify the location of their SRP. Children age 7 and above who 
could read and had sufficient motor skills for independently self-administering a 
questionnaire could answer questions about pain severity in relation to specific 
activities, but were not able to reliably address the frequency or duration of their 
pain. Children 5-7 years (and those with more severe CP) who were able to 
communicate answered the same items but in interviewer-administered format. 
Parent/caregivers could report on observed signs of pain in their children but not 
address the subjective intensity of that pain. They could, however, report on the 
frequency of those signs of pain. Because direct attention and close contact time 
between parent/caregivers and children with CP varies, parent/caregiver 
observations of the duration of pain was less reliable. CONCLUSIONS: Direct 
correspondence of items addressing key concepts (e.g. presence of SRP) can 
provide an anchor for combining patient reported and observer reported 
information and relating the various descriptive aspects around the concepts 
being measured to provide a more complete and richer dataset for compromised 
populations where assessment is challenging.  
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OBJECTIVES: To develop a patient-reported outcome (PRO) measure to assess the 
key symptoms of chronic low back pain (cLBP) through qualitative concept 
elicitation (CE) and cognitive interviews. METHODS: Adult patients (18-80 years) 
with clinical diagnoses of cLBP of non-malignant origin and current pain scores 
≥4 on a 0-10 numerical rating scale (NRS) were recruited in the U.S., UK, and 
Germany. Trained interviewers conducted CE and cognitive interview sessions 
with participating patients using semi-structured interview guides. The CE 
interviews elicited spontaneous reports of symptom experiences followed by 
probing to further explore and confirm concepts. The cognitive interviews 
evaluated the degree of patient comprehension of the items in the draft PRO 
measure. All interview sessions were audio recorded and transcribed. The CE 
interviews were coded for qualitative content analysis using Atlas.ti, and the 
cognitive interview transcripts were summarized in cognitive report tables. 
RESULTS: Forty-three CE interviews were conducted (mean age: 48.6±13.0, 53.5% 
female, 74.4% -White/Caucasian). Mean pain NRS score was 6.7± 1.3. A total of 
1342 symptom codes were derived from the transcripts, representing 32 different 
symptom concepts. Data from CE interviews was considered alongside existing 
measures, published literature and expert opinion to develop a 23-item draft 
measure. Thirty additional patients participated in four waves of cognitive 
interviews, during which nine items were removed and others were 
substantially modified to create the Pain Assessment for Low Back Symptoms 
(PAL-S). CONCLUSIONS: The PAL-S is a 14-item PRO measure for assessing 
symptoms of cLBP that has been developed through direct qualitative patient 
involvement in accordance with the FDA’s PRO Guidance and scientific best 
practices. Cognitive interviews have provided evidence from patients that the 
measure is comprehensive, relevant to their cLBP experience, comprehendible, 
